Menu
Enrolling by invitation NCT06846814

Second-Look Ultrasound Post Contrast-Enhanced Mammography for Additional Lesions Characterization

Observational Breast Cancer Diagnosis Breast Cancer Detection

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CEM protocol.
Who it may be relevant to
Registry conditions: Breast Cancer Diagnosis, Breast Cancer Detection. Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study investigates the utility of second-look ultrasound (US) following contrast-enhanced mammography (CEM) to characterize additional lesions detected during routine breast imaging.

Detailed description

The goal is to assess the diagnostic accuracy and clinical value of combining CEM with targeted ultrasound to improve lesion characterization and guide biopsy decisions.

Interventions

  • Diagnostic test CEM protocol
    The intervention consists of Second-Look Ultrasound (SLUS) performed following Contrast-Enhanced Mammography (CEM) to further evaluate additional lesions detected during routine breast imaging. When CEM identifies additional or suspicious lesions not clearly characterized by mammography alone, targeted ultrasound is conducted to assess lesion morphology, vascularity, and acoustic characteristics. Radiologists with expertise in both CEM and ultrasound interpretation will perform SLUS to determin

Primary outcome measures

  • Detection Rate of Additional Lesions on CEM [Time frame: Within 12 months of imaging assessment.]
Secondary outcome measures (2)
  • Concordance Between Imaging Findings and Histopathology [Time frame: Up to 3 months post-biopsy.]
  • Concordance Between Imaging Findings and Follow-Up Imaging [Time frame: 6-12 months after the initial CEM examination]

Eligibility criteria

Inclusion criteria

  • Patients undergoing contrast-enhanced mammography for diagnostic or surveillance purposes.
  • Identification of additional lesions on CEM requiring further evaluation.
  • Ability to provide informed consent.

Exclusion criteria

  • Known breast cancer diagnosis without suspicion of additional lesions.
  • Contraindications to ultrasound or contrast agents.
  • Patients with incomplete imaging data.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Italy · 1 center
  • University of Campania Luigi Vanvitelli — Naples

Identifiers

NCT: NCT06846814 · T_4_2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗